{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":10,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02282020\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SOLO3","nct_id":"NCT02282020","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=solo3-nct02282020. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"SOLO3","arms":[{"description":"olaparib 300mg oral tablets; twice daily","label":"1/OLAPARIB","type":"EXPERIMENTAL"},{"description":"Physician's choice single agent chemotherapy","label":"2/CHEMOTHERAPY","type":"ACTIVE_COMPARATOR"}],"collaborators":["Myriad Genetic Laboratories, Inc.","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2022-07-19","type":"ACTUAL"},"conditions":["Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity"],"enrollment":{"count":266,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"OLAPARIB","type":"DRUG"},{"name":"Single agent chemotherapy","type":"DRUG"}],"last_update":"2022-07-26","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-10-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)"}],"references":[{"citation":"Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernandez C, Mora PAR, Ryu SY, Ah-See ML, Lowe ES, Lukashchuk N, Carter D, Penson RT. Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. J Clin Oncol. 2025 Apr 20;43(12):1408-1416. doi: 10.1200/JCO.24.00933. Epub 2024 Dec 12.","pmid":"39668137","type":"DERIVED"},{"citation":"Paulino E, Melo AC. SOLO 3 Trial: How Do the Results Fit in With Current Evidence? J Clin Oncol. 2020 Aug 10;38(23):2697-2698. doi: 10.1200/JCO.20.00576. Epub 2020 Jun 12. No abstract available.","pmid":"32530768","type":"DERIVED"},{"citation":"Penson RT, Lowe ES. Reply to E. Paulino et al. J Clin Oncol. 2020 Aug 10;38(23):2698. doi: 10.1200/JCO.20.01235. Epub 2020 Jun 12. No abstract available.","pmid":"32530766","type":"DERIVED"},{"citation":"Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernandez C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.","pmid":"32073956","type":"DERIVED"}],"start_date":{"date":"2015-02-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","url":"https://clinicaltrials.gov/study/NCT02282020"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/solo3-nct02282020"}